MCAG adds newly formed entities as parties to AUM Biosciences merger agreement

Mountain Crest Acquisition Corp. V

Joinder Agreement dated Jan 27, 2023 admits Holdco (AUM Biosciences Limited), Amalgamation Sub, and Merger Sub to the Oct 19, 2022 Business Combination Agreement.
Holdco will become the publicly traded holding company; Amalgamation Sub will merge into AUM Biosciences; Merger Sub will merge into SPAC.
No changes to transaction terms, consideration, or closing conditions were disclosed in the joinder.
All newly formed entities are wholly-owned subsidiaries of Holdco.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Mountain Crest Acquisition Corp. V amended Business Combination Agreement with AUM Biosciences Pte. Ltd., AUM Biosciences Limited, AUM Biosciences Subsidiary Pte. Ltd., AUM Biosciences Delaware Merger Sub, Inc. (effective 2023-01-27).

Action: amendment
Agreement: merger
Counterparty: AUM Biosciences Pte. Ltd., AUM Biosciences Limited, AUM Biosciences Subsidiary Pte. Ltd., AUM Biosciences Delaware Merger Sub, Inc.
Effective: 2023-01-27

Exact text from the filing

On January 27, 2023, SPAC, the Company, AUM Biosciences Limited, AUM Biosciences Subsidiary Pte. Ltd. and AUM Biosciences Delaware Merger Sub, Inc. entered into a joinder agreement to the Business Combination Agreement (the “Joinder Agreement”), that expressly amended and modified the Business Combination Agreement

View on SEC.gov

Browse all material agreements →

Mountain Crest Acquisition Corp. V filing history →

Source: SEC EDGAR

accession 0001829126-23-001150

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.